DNDN best observed from a distance

It's been a week since I paid much attention to the market, particularly Dendreon. Once burned severely by this stock (and a corrupt FDA), I prefer to keep my distance and watch from afar. Since last week's news that Congress may probe the FDA's rejection of Provenge, the stock has slumped as low as sub-$6. Not my type of stock.